Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tonsitin
- Development stage
- Phase 2
- Lead developer
- Shamir Medical Center
- Administration
- Oral
01
Overview
**Tonsitin** is a 10% DL-lactic acid syrup formulated as a raspberry-flavored oral dietary supplement for treating recurrent tonsillitis (RT) in children aged 5-16. It has demonstrated good tolerability and safety in a randomized, double-blind pilot study involving 51 children with at least 4 tonsillitis episodes per year, showing mild adverse events in a small subset and non-significant reductions in tonsil size and episode frequency. Developed for clinical use in outpatient settings, it is administered twice daily for one month, with evaluations up to 6 months post-treatment focusing on safety, tonsil size, recurrence rates, and quality of life.[1][3][5]
- Brand names
- Tonsitin
- Other names
- LA-001-ILLA001-ILLA 001-IL
Beyond the preview
Go deeper on Tonsitin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tonsitin.